Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging

The differentiation of multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) from idiopathic Parkinson's disease (IPD) is difficult. Magnetization transfer imaging (MTI), a measure that correlates with myelination and axonal density, was employed in this study in the attempt to distinguish between these disorders. Measurements were carried out in 15 patients with IPD, 12 patients with MSA, 10 patients with PSP, and in 20 aged-matched healthy control subjects. The main finding was a change in the magnetization transfer ratio in the globus pallidus, putamen, caudate nucleus, substantia nigra, and white matter in IPD, MSA, and PSP patients, matching the pathological features of the underlying disorder. Furthermore, stepwise linear discriminant analysis provided a good classification of the individual patients into the different disease groups. All IPD patients and control subjects were correctly separated from the MSA and PSP cohort, and all PSP patients and 11 of 12 MSA patients were correctly separated from the IPD and control cohort. There was also a fairly good discrimination of IPD patients from control subjects and of MSA from PSP patients. In conclusion, MTI revealed degenerative changes in patients with different parkinsonian syndromes matching the underlying pathological features of the different diseases, underlining the high potential of this method in distinguishing MSA and PSP from IPD.

[1]  L. Golbe,et al.  Prevalence and natural history of progressive supranuclear palsy , 1988, Neurology.

[2]  Shozo Tobimatsu,et al.  Cerebral metabolic changes in early multiple system atrophy: a PET study , 2002, Journal of the Neurological Sciences.

[3]  J. Rademacher,et al.  Measuringin VivoMyelination of Human White Matter Fiber Tracts with Magnetization Transfer MR , 1999, NeuroImage.

[4]  David J. Brooks,et al.  A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson’s disease , 2001, Neurology.

[5]  A. Benabid,et al.  Opposite motor effects of pallidal stimulation in Parkinson's disease , 1998, Annals of neurology.

[6]  Brian Ross Basic Physics of MRS , 1999 .

[7]  I. Shoulson,et al.  Experimental therapeutics of neurodegenerative disorders: unmet needs. , 1998, Science.

[8]  Brian D. Ross,et al.  Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases , 1999 .

[9]  S. Fahn Unified Parkinson's Disease Rating Scale , 1987 .

[10]  S. Nakamura,et al.  Apparent diffusion coefficient measurements in progressive supranuclear palsy , 2000, Neuroradiology.

[11]  J R Moeller,et al.  Early differential diagnosis of Parkinson's disease with 18F‐fluorodeoxyglucose and positron emission tomography , 1995, Neurology.

[12]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[13]  M Hutchinson,et al.  Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. , 2000, AJNR. American journal of neuroradiology.

[14]  Yulin Ge,et al.  Age-related total gray matter and white matter changes in normal adult brain. Part II: quantitative magnetization transfer ratio histogram analysis. , 2002, AJNR. American journal of neuroradiology.

[15]  Tetsuya Mori,et al.  Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration , 2002, Journal of the Neurological Sciences.

[16]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[17]  F Federico,et al.  Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[18]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[19]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[20]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[21]  C. Marsden,et al.  Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy , 1995, Annals of neurology.

[22]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[23]  R. Balaban,et al.  Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo , 1989, Magnetic resonance in medicine.

[24]  C. Good,et al.  Differentiation of atypical parkinsonian syndromes with routine MRI , 2000, Neurology.

[25]  Johannes Schwarz,et al.  Steele‐Richardson‐Olszewski‐Syndrome: Reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: 123IBZM SPECT and MRI study , 2002, Movement disorders : official journal of the Movement Disorder Society.

[26]  Irene Litvan,et al.  Progressive supranuclear palsy : clinical and research approaches , 1992 .

[27]  M. Pui,et al.  Magnetization transfer analysis of brain tumor, infection, and infarction , 2000, Journal of magnetic resonance imaging : JMRI.

[28]  J. Jankovic,et al.  Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy , 1998, Journal of Neural Transmission.

[29]  R I Grossman,et al.  Dyke Award paper. MR of wallerian degeneration in the feline visual system: characterization by magnetization transfer rate with histopathologic correlation. , 1994, AJNR. American journal of neuroradiology.

[30]  M. Muenter,et al.  Multi‐center study of Parkinson mortality with early versus later dopa treatment , 1987, Annals of neurology.

[31]  H. Hanyu,et al.  Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson's disease with and without dementia and in progressive supranuclear palsy , 2001, Neuroradiology.

[32]  V. Dhawan,et al.  Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET , 1998, Movement disorders : official journal of the Movement Disorder Society.

[33]  M Rovaris,et al.  Correlations Between Clinical Findings and Magnetization Transfer Imaging Metrics of Tissue Damage in Individuals With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy , 2001, Stroke.

[34]  R I Grossman,et al.  Magnetization transfer imaging in the detection of injury associated with mild head trauma. , 2000, AJNR. American journal of neuroradiology.

[35]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.

[36]  W. Heiss,et al.  Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging , 2002, Journal of neurology, neurosurgery, and psychiatry.

[37]  R E Lenkinski,et al.  Magnetization transfer imaging of diffuse axonal injury following experimental brain injury in the pig: characterization by magnetization transfer ratio with histopathologic correlation. , 1996, Journal of computer assisted tomography.

[38]  Francesco Federico,et al.  Proton magnetic resonance spectroscopy in parkinson's disease and atypical parkinsonian disorders , 1997 .

[39]  N. Quinn,et al.  Multiple system atrophy: A review of 203 pathologically proven cases , 1997, Movement disorders : official journal of the Movement Disorder Society.

[40]  A Benazzouz,et al.  Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. , 1995, AJNR. American journal of neuroradiology.

[41]  C. Manelfe,et al.  Diffusion- and magnetisation transfer-weighted MRI in childhood moya-moya , 1998, Neuroradiology.

[42]  A. Lees,et al.  A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.

[43]  D. Margouleff,et al.  Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease , 1993, Annals of neurology.

[44]  M Filippi,et al.  Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosis , 1998, Annals of neurology.

[45]  I Litvan,et al.  What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. , 1997, Archives of neurology.

[46]  N. Schuff,et al.  Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[47]  G. Barker,et al.  Correlation of magnetization transfer ration with clinical disability in multiple sclerosis , 1994, Annals of neurology.

[48]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[49]  C Kremser,et al.  Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.

[50]  C Kremser,et al.  Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD , 2002, Neurology.

[51]  Shigenobu Nakamura,et al.  Magnetization Transfer Measurements of Brain Structures in Patients with Multiple System Atrophy , 2002, NeuroImage.

[52]  I Litvan,et al.  Consensus statement on the diagnosis of multiple system atrophy , 1998, Journal of the Neurological Sciences.

[53]  M. Skalej,et al.  Magnetic resonance imaging–based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy , 1999, Annals of neurology.

[54]  P. R. Hof,et al.  Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: A quantitative analysis of six cases , 2004, Acta Neuropathologica.

[55]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[56]  Björn Gustavii,et al.  Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease , 1997, Annals of neurology.

[57]  W. M. van der Flier,et al.  Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease , 2002, Annals of neurology.

[58]  Daniela Berg,et al.  Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.

[59]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[60]  G J Barker,et al.  Magnetisation transfer ratio of normal brain white matter: a normative database spanning four decades of life. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[61]  Y Agid,et al.  Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. , 1985, Brain : a journal of neurology.